peptide injections retatrutide Retatrutide: The New Triple-Agonist Weight Loss Treatment What Is Retatrutide? | Research-Use

David Joffe, BSPharm, CDE Tina Burge, PharmD Candidate Florida A&M University Kiet Ngo, Pharm D Candidate Mercer University Abnormalities in incretin hormones such as the glucagon-like peptide-1 (GLP-1) contribute to the development of hyperglycemia

*Based on STEP 1 pharmaceutical trial

It stands out with its coaching, community, and full range of treatment options, including oral and injectable GLP-1s, and non-GLP-1 medications that may be used alone or in combination for a tailored approach

GLP-1 Receptor Agonist Market Opportunities: Expanded cardiovascular indications and biosimilar development creating transformative GLP-1 receptor agonist market opportunities The cardiovascular indication expansion following SELECT trial approval for semaglutide in cardiovascular risk reduction in obese non-diabetic patients is qualitatively important because it changes who prescribes GLP-1 drugs